Pharmaron Holding Ltd., an Irvine research and development company, has raised $40 million in a third round of funding.
Pharmaron said it would use the money to expand drug discovery services, pre-clinical toxicology capabilities and chemical synthesis services. The company works with drug and device makers.
DCM of Menlo Park, and two Chinese investors, Legend Capital and GL Capital Group, participated in Pharmaron’s funding. DCM and Legend are returning investors, while GL is a new investor.
Pharmaron was founded in 2003 and also has operations in Beijing and Louisville, Ky. The company has more than 1,200 workers; in a release, it said its clients included small and large drug makers in North America, Europe and Japan.
